ID   EW-8
AC   CVCL_1658
AS   CVCL_5915; CVCL_V618
SY   EW8; EW8(Rh1); RH1; Rh1; RH-1; Rh-1; SJRH-1; SJRH1
DR   BTO; BTO_0005378
DR   CLO; CLO_0009878
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-3610
DR   BioGRID_ORCS_Cell_line; 172
DR   BioSample; SAMN03473566
DR   BioSample; SAMN10988420
DR   cancercelllines; CVCL_1658
DR   Cell_Model_Passport; SIDM00427
DR   Cell_Model_Passport; SIDM01500
DR   ChEMBL-Cells; CHEMBL3308524
DR   ChEMBL-Targets; CHEMBL2366078
DR   Cosmic; 801755
DR   Cosmic; 971773
DR   Cosmic; 1037294
DR   Cosmic; 1048107
DR   Cosmic; 1097750
DR   Cosmic; 1104556
DR   Cosmic; 1108744
DR   Cosmic; 2228229
DR   Cosmic; 2294583
DR   Cosmic-CLP; 971773
DR   DepMap; ACH-000499
DR   DepMap; ACH-002194
DR   DSMZ; ACC-493
DR   DSMZCellDive; ACC-493
DR   EGA; EGAS00001000978
DR   GDSC; 971773
DR   GEO; GSM1670376
DR   GEO; GSM1676298
DR   GEO; GSM1701633
DR   GEO; GSM5359688
DR   GEO; GSM5359689
DR   GEO; GSM5359690
DR   GEO; GSM5359691
DR   GEO; GSM5359692
DR   GEO; GSM5359693
DR   GEO; GSM5362948
DR   GEO; GSM5362949
DR   GEO; GSM5362950
DR   GEO; GSM5362951
DR   GEO; GSM5362952
DR   GEO; GSM5362953
DR   GEO; GSM5363996
DR   GEO; GSM5363997
DR   GEO; GSM5363998
DR   GEO; GSM5363999
DR   GEO; GSM5364000
DR   IARC_TP53; 27229
DR   LINCS_LDP; LCL-1456
DR   PharmacoDB; EW8_361_2019
DR   PharmacoDB; RH1_1310_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_V618
DR   PubChem_Cell_line; CVCL_1658
DR   Wikidata; Q54833004
RX   DOI=10.5282/edoc.27750;
RX   PubMed=7536457;
RX   PubMed=8275086;
RX   PubMed=11051265;
RX   PubMed=17154184;
RX   PubMed=20164919;
RX   PubMed=23578105;
RX   PubMed=23882450;
RX   PubMed=25010205;
RX   PubMed=25984343;
RX   PubMed=26351324;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=35839778;
RX   PubMed=36476851;
WW   Info; ESCLA; -; https://hgserver1.amc.nl/cgi-bin/r2/main.cgi?option=about_dscope
CC   Problematic cell line: Misclassified. Originally thought to be a rhabdomyosarcoma cell line but shown to be from an Ewing sarcoma (PubMed=17154184).
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: Ewing Sarcoma Cell Line Atlas (ESCLA).
CC   Population: Caucasian.
CC   Doubling time: 30 hours (PubMed=25984343); ~30-40 hours (DSMZ=ACC-493).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Gene fusion; HGNC; HGNC:3508; EWSR1 + HGNC; HGNC:3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1; Note=Type 1 fusion (Ex7/Ex6) (PubMed=17154184; PubMed=25010205; PubMed=36476851).
CC   Sequence variation: Mutation; HGNC; HGNC:6342; KIT; Simple; p.Arg55Trp (c.163A>T); Zygosity=Heterozygous (Cosmic-CLP=971773; DepMap=ACH-000499).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Tyr220Cys (c.659A>G); ClinVar=VCV000127819; Zygosity=Homozygous (PubMed=25010205; Cosmic-CLP=971773; DepMap=ACH-000499).
CC   Omics: Genomics; ChIP-seq; FLI1.
CC   Omics: Genomics; ChIP-seq; H3K27ac.
CC   Omics: Genomics; ChIP-seq; H3K27me3.
CC   Omics: Genomics; ChIP-seq; H3K4me3.
CC   Omics: Genomics; DNA methylation analysis.
CC   Omics: Genomics; Whole exome sequencing.
CC   Omics: Genomics; Whole genome sequencing.
CC   Omics: Phenotyping; Drug screening.
CC   Omics: Phenotyping; shRNA library screening.
CC   Omics: Proteomics.
CC   Omics: Proteomics; Quantitative.
CC   Omics: Transcriptomics; Microarray.
CC   Omics: Transcriptomics; RNAseq.
CC   Omics: Variations; SNP array analysis.
CC   Genome ancestry: African=0%; Native American=0%; East Asian, North=1.08%; East Asian, South=0%; South Asian=0%; European, North=66.53%; European, South=32.38% (PubMed=30894373).
CC   Discontinued: DepMap; ACH-002194; true.
CC   Derived from site: Metastatic; Bone marrow; UBERON=UBERON_0002371.
ST   Source(s): Cosmic-CLP=971773; DSMZ=ACC-493; PubMed=25010205
ST   Amelogenin: X,Y
ST   CSF1PO: 11
ST   D13S317: 10
ST   D16S539: 13
ST   D18S51: 15
ST   D19S433: 13,15.2 (PubMed=25010205)
ST   D19S433: 13,16 (DSMZ=ACC-493)
ST   D21S11: 29,30
ST   D2S1338: 16,19
ST   D3S1358: 11,18 (PubMed=25010205)
ST   D3S1358: 18 (DSMZ=ACC-493)
ST   D5S818: 11
ST   D7S820: 8,12
ST   D8S1179: 14,16
ST   FGA: 22,23
ST   Penta D: 9,13
ST   Penta E: 5,16
ST   TH01: 9.3
ST   TPOX: 8
ST   vWA: 17
DI   NCIt; C4817; Ewing sarcoma
DI   ORDO; Orphanet_319; Ewing sarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 10-04-25; Version: 44
//
RX   DOI=10.5282/edoc.27750;
RA   Orth M.F.;
RT   "Systematic multi-omics profiling of Ewing sarcoma cell lines.";
RL   Thesis PhD (2021); Ludwig Maximilians University of Munich; Munich; Germany.
//
RX   PubMed=7536457; DOI=10.1002/gcc.2870120305;
RA   Biegel J.A., Nycum L.M., Valentine V.A., Barr F.G., Shapiro D.N.;
RT   "Detection of the t(2;13)(q35;q14) and PAX3-FKHR fusion in alveolar
RT   rhabdomyosarcoma by fluorescence in situ hybridization.";
RL   Genes Chromosomes Cancer 12:186-192(1995).
//
RX   PubMed=8275086; DOI=10.1038/ng1193-230;
RA   Galili N., Davis R.J., Fredericks W.J., Mukhopadhyay S.,
RA   Rauscher F.J. 3rd, Emanuel B.S., Rovera G., Barr F.G.;
RT   "Fusion of a fork head domain gene to PAX3 in the solid tumour
RT   alveolar rhabdomyosarcoma.";
RL   Nat. Genet. 5:230-235(1993).
//
RX   PubMed=11051265;
RA   Petak I., Douglas L., Tillman D.M., Vernes R., Houghton J.A.;
RT   "Pediatric rhabdomyosarcoma cell lines are resistant to Fas-induced
RT   apoptosis and highly sensitive to TRAIL-induced apoptosis.";
RL   Clin. Cancer Res. 6:4119-4127(2000).
//
RX   PubMed=17154184; DOI=10.1002/pbc.21099;
RA   Smith M.A., Morton C.L., Phelps D.A., Girtman K., Neale G.,
RA   Houghton P.J.;
RT   "SK-NEP-1 and Rh1 are Ewing family tumor lines.";
RL   Pediatr. Blood Cancer 50:703-706(2008).
//
RX   PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113;
RA   Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=23578105; DOI=10.1111/cas.12173; PMCID=PMC7657110;
RA   Nishimura R., Takita J., Sato-Otsubo A., Kato M., Koh K., Hanada R.,
RA   Tanaka Y., Kato K., Maeda D., Fukayama M., Sanada M., Hayashi Y.,
RA   Ogawa S.;
RT   "Characterization of genetic lesions in rhabdomyosarcoma using a
RT   high-density single nucleotide polymorphism array.";
RL   Cancer Sci. 104:856-864(2013).
//
RX   PubMed=23882450; DOI=10.3389/fonc.2013.00183; PMCID=PMC3713458;
RA   Hinson A.R.P., Jones R., Crose L.E.S., Belyea B.C., Barr F.G.,
RA   Linardic C.M.;
RT   "Human rhabdomyosarcoma cell lines for rhabdomyosarcoma research:
RT   utility and pitfalls.";
RL   Front. Oncol. 3:183.1-183.12(2013).
//
RX   PubMed=25010205; DOI=10.1371/journal.pgen.1004475; PMCID=PMC4091782;
RA   Brohl A.S., Solomon D.A., Chang W., Wang J.-J., Song Y., Sindiri S.,
RA   Patidar R., Hurd L., Chen L., Shern J.F., Liao H.-L., Wen X.-Y.,
RA   Gerard J., Kim J.-S., Lopez Guerrero J.A., Machado I., Wai D.H.,
RA   Picci P., Triche T.J., Horvai A.E., Miettinen M.M., Wei J.S.,
RA   Catchpoole D., Llombart-Bosch A., Waldman T.A., Khan J.;
RT   "The genomic landscape of the Ewing sarcoma family of tumors reveals
RT   recurrent STAG2 mutation.";
RL   PLoS Genet. 10:e1004475.1-e1004475.13(2014).
//
RX   PubMed=25984343; DOI=10.1038/sdata.2014.35; PMCID=PMC4432652;
RA   Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S.,
RA   East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H.,
RA   Jiang G.-Z., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M.,
RA   Harrington W., Gelfand E.T., Green T.M., Tomko M.J., Gopal S.,
RA   Wong T.C., Li H.-B., Howell S., Stransky N., Liefeld T., Jang D.,
RA   Bistline J., Meyers B.H., Armstrong S.A., Anderson K.C.,
RA   Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P.,
RA   Golub T.R., Root D.E., Hahn W.C.;
RT   "Parallel genome-scale loss of function screens in 216 cancer cell
RT   lines for the identification of context-specific genetic
RT   dependencies.";
RL   Sci. Data 1:140035.1-140035.12(2014).
//
RX   PubMed=26351324; DOI=10.1158/1535-7163.MCT-15-0074; PMCID=PMC4636476;
RA   Teicher B.A., Polley E.C., Kunkel M.W., Evans D., Silvers T.E.,
RA   Delosh R.M., Laudeman J., Ogle C., Reinhart R., Selby M., Connelly J.,
RA   Harris E., Monks A., Morris J.;
RT   "Sarcoma cell line screen of oncology drugs and investigational agents
RT   identifies patterns associated with gene and microRNA expression.";
RL   Mol. Cancer Ther. 14:2452-2462(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3; PMCID=PMC6697103;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. 3rd, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010; PMCID=PMC9387775;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//
RX   PubMed=36476851; DOI=10.1016/j.celrep.2022.111761; PMCID=PMC10333306;
RA   Orth M.F., Surdez D., Faehling T., Ehlers A.C., Marchetto A.,
RA   Grossetete-Lalami S., Volckmann R., Zwijnenburg D.A., Gerke J.S., Zaidi S.,
RA   Alonso J., Sastre A., Baulande S., Sill M., Cidre-Aranaz F., Ohmura S.,
RA   Kirchner T., Hauck S.M., Reischl E., Gymrek M., Pfister S.M., Strauch K.,
RA   Koster J., Delattre O., Grunewald T.G.P.;
RT   "Systematic multi-omics cell line profiling uncovers principles of
RT   Ewing sarcoma fusion oncogene-mediated gene regulation.";
RL   Cell Rep. 41:111761.1-111761.28(2022).
//